National Pharmaceutical Pricing Authority

(Published in Part II, Section 3, Sub-section (ii) of

the Gazette of India, Extraordinary, dated the 27^th November, 2008)

Government of India

Ministry of Chemicals and Fertilizers

National Pharmaceutical Pricing Authority

New Delhi, the 27^th November, 2008

ORDER

S.O. 2805(E)- In exercise of the powers, conferred by sub-paragraph (1)/(2)/(4) of paragraph 8 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637 (E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority, hereby fixes/revises the prices as specified in column (5) of the table hereto annexed as the retail price/revised retail price, exclusive of excise duty, Sales Taxes/VAT and local taxes, if any, and in column (6) as equivalent MRP inclusive of excise duty, education cess, Sales Tax/VAT in relation to each of the formulation specified in the corresponding entry in column (2) of the said table with the pack size specified in the corresponding entries in column (3) thereof; manufactured/imported by M/s. Eli Lilly and Company (I) Pvt. Ltd.

TABLE

Sl. No.	Name of the formulation	Pack Size	Existing Retail Price Excise (Rs.)	Retail Price without Excise Duty Sales Tax /VAT and Local Tax, if any (Rs.)	Equivalent MRP* inclusive of all taxes (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
1	Monocomponent Insulin Huminsulin NPH 100 IU/ml (Isophane Insulin Human Suspension) Each ml contains Human Insulin Ph Eur.(r-DNA origin) 100 as active ingredient – 100IU Batch No. A508566G / Qty. 14730 Cartridges imported	3ml Cartridge	203.05	202.97	211.09
2	Monocomponent Insulin Huminsulin 30/70 – 100 IU/ml (30% Neutral Insulin Solution & 70% Isophane Suspension Human) Anti Diabetc Each ml of 30% Neutral Insulin Solution & 70% Isophane Suspension Human contains: 100 IU Human insulin Ph. Eur. (r-DNA origin) as active ingredient Batch No. A502108C /Qty. 149980 Cartridges imported	3ml Cartridge	203.05	202.97	211.09
3	Monocomponent Insulin Humalog Mix 50 100IU/ml 50% Insulin Lispro and50% Insulin Lispro Protamine Suspension, r-DNA Origin Anti Diabetic (Insulin Lispro) Each ml of 50% Insulin Lispro and 50% Insulin Lispro Protamine suspension contains 100 IU Insulin Lispro (r-DNA Origin) as Active ingredient No. A473663A / Qty. 35270 Cartridge Imported	3ml Cartridge	397.26	397.12	413.00
4	Monocomponent Insulin Humalog 100 IU/ml (Insulin Lispro) Anti Diabetic Each ml of Insulin Lispro contains 100 IU (3.5mg) Insulin Lispro (r-DNA origin) as active ingredient Batch No. A493325D / Qty. 36635 Cartridges imported	3ml Cartridge	397.26	397.12	413.00
5	Monocomponent Insulin Humalog Mix 25 100 IU/ml 25% Insulin Lispro and 75% InsulinLispro Protamine suspension, r-DNA origin, Anti Diabetic Each ml of 25% Insulin Lispro and 75% Insulin LisproProtamine suspension contains 100 IU Insulin Lispro (r-DNA origin) as active ingredient Batch No. A498235K / Qty. 30200 Cartridges imported	3ml Cartridge	397.26	397.75	413.66
6	Monocomponent Insulin Huminsulin 30/70 – 40 IU/ml Vial (30% Neutral Insulin Solution & 70%Isophane Suspension Human) Each ml of 30% Neutral Insulin Solution & 70% Isophane Suspension Human contains: 40 IU Humaninsulin Ph. Eur. (r-DNA origin) as active ingredient Batch No. A518010 / Qty. 47213 Vials imported Batch No. A518011 / Qty. 47208 Vials imported Batch No. A518008 / Qty. 47215 Vials imported Batch No. A518009 / Qty. 47410 Vials imported Batch No. A522805 / Qty. 47540 Vials imported Batch No. A525407 / Qty. 47173 Vials imported Batch No. A527363 / Qty. 46389 Vials imported Batch No. A525406 / Qty. 47215 Vials imported Batch No. A550675 / Qty. 46795 Vials imported Batch No. A527364 / Qty. 47597 Vials imported	10mlVial	158.00	158.00	164.32
7	Monocomponent Insulin Huminsulin 30/70 – 100 IU/ml Vial(30% Neutral Insulin Solution & 70% Isophane Suspension Human) Anti Diabetc Each ml of 30% Neutral Insulin Solution &70% Isophane Suspension Human contains: 100 IU Human insulin Ph. Eur. (r-DNA origin) as active ingredient Batch No. HIM392 / 16083 Vials imported	10mlVial	369.39	369.34	384.11
8	Monocomponent Insulin Huminsulin NPH 100 IU/ml (Isophane Insulin Human Suspension) Each ml contains Human Insulin Ph Eur.(r-DNA origin) 100 as active ingredient – 100IU Batch No. HIN083 / Qty. 6783 Vials imported	10mlVial	369.12	369.34	384.11
9	Monocomponent Insulin Huminsulin Regular 100 IU/ml Vial (Insulin Human Injection) Each ml of Insulin Human Injection contains : 100 IU Human Insulin Ph. Eur. (r-DNA Origin)as active ingredient No. HIR090A, Qty. 11708 Vials imported	10mlVial	369.12	369.34	384.11

*Subject to actual payment of Government levies/taxes, as applicable.

Note :

(a) The prices fixed are the maximum retail prices in column no. (6) (inclusive of excise duty, sales tax/VAT and local taxes if any) for the specified pack and packs of similar strength, and companies cannot claim exemption on any ground therefrom, unless specifically permitted by the Government/NPPA through an order.

(b) The companies / manufacturers may added taxes only if they have paid actually to the Government on the price mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be intimated to the NPPA in the Form-V of DPCO, 1995.

(c) For different packing material used or any special feature claimed, companies are required to approach NPPA for approval/fixation of specific prices.

(d) The manufacturer and marketing company for the above said formulation shall be required to take the requisite prior approval from the competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.

(e) These prices/revised prices shall be made effective within 15 days of receipt of this order as required under sub para 14(1) of DPCO, 1995. The necessary price-list should also be issued as required under sub-paragraph (3) of paragraph 14 of the Drugs (Prices Control) Order, 1995.

(f) These prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented by the manufacturing/marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940.

PN/105/2008/F

F. No. 8(14)/2008/D.P./NPPA-Div.-II

(RAJIV WADHAWAN)

Deputy Director

Last Page Updated: 01-06-2019

Note :Website Content Managed by National Pharmaceutical Pricing Authority Ministry of Chemicals and Fertilizers, Designed, Developed and Hosted by National Informatics Centre Services Inc.(NICSI)